Answers are grounded in this paper and cite their sources.
Inviting Innovationsd) age of onset less than 25 years; e) positive family history and f) cessation of focal sweating during sleep [4].Secondary hyperhidrosis on the other hand, can be drug-induced, toxin-induced, caused by a systemic illness, by congenital disorders or it can be compensatory [5].Currently, treatment options available include pharmacologic and surgical.Pharmacologic treatments include topical aluminum salts, iontophoresis, systemic medications (i.e.glycopyrrolate, menthatheline bromide, oxybutynin and clonidine) and botulinum toxin injection.Meanwhile, surgical treatments include liposuction, direct excision of the glands, sympathectomy [4] and laser treatment.The limitations of the aforementioned treatments are: a) provide only temporary results; b) have disabling side effects; c) may be expensive; and d) some are more invasive that may lead to complications.Sclerotherapy is the use of physical, chemical, and biological properties of an agent used to disrupt target tissue.Sclerosants induce inflammatory response that result to fibrosis, thrombosis, extraction of proteins from lipids, denaturation of proteins, cell dehydration by osmosis, and physical obstruction by polymerization.The result of these processes is controlled disruption of the targeted tissues' biologic function [6].Sclerosing solutions include ethanol, hypertonic saline, sodium tetradecyl sulfate, polidocanol, sodium morrhuate, polyiodide iodide and glycerin [6,7].In dermatology, sclerotherapy is commonly indicated for the treatment of insufficient veins, recurrent varicosities and venous malformations [8].In our literature search, there are only a few studies regarding the use of sclerotherapy, specifically ethanol, for chemical ablation of the sweat glands to treat axillary osmidrosis [10,11] but, none yet for polidocanol and for axillary hyperhidrosis.Hence, this study aims to investigate the use of polidocanol as a novel therapeutic option in providing a permanent, cost-effective and less invasive method in treating primary axillary hyperhidrosis. MethodologyStudy design and study population least 6 months duration without apparent cause with at least two of the following characteristics: a) bilateral and relatively symmetric; b) impairs daily activities; c) frequency of at least one episode per week;
No takes yet. Share an insight, caveat, or question.
A 2020 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: